Skip to main content
S&P 5007,568.96+0.37%DOW51,786.15-0.38%NASDAQ25,372.01+0.83%BTC$77,820.00+1.51%ETH$2,290.23+2.01%GOLD$3,931.20-0.97%OIL$96.52+0.06%
Smart Investors Daily
SID Premium
WG

NASDAQ · WGS

GeneDx Holdings Corp.

Healthcare · Medical - Healthcare Information Services

$64.09

Up+$4.55 (+7.10%)

Updated Nov 3, 2026, 9:03 PM

SID Score

3.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.49B
P/E ratio
2,147.87
Dividend yield
0.00%
52-week range
$32.21 – $105.18
Volume
1.15M
Avg. volume
519.06K

Price performance · WGS

WGS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

WGS closed at $64.09 after 21 trading sessions, down 15.97% for the selected period.

Last close
$64.09
Period change
-15.97%
Period low
$56.15
Period high
$76.27
Daily close
View OHLC price history
WGS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$69.15$69.53$63.605$64.091.15M
Oct 30, 2026$69.32$70.99$66.80$69.06886.15K
Oct 29, 2026$65.55$71.50$64.48$71.02921.75K
Oct 28, 2026$63.19$67.47$63.19$64.69575.05K
Oct 27, 2026$62.11$65.72$60.77$62.74926.94K
Oct 26, 2026$58.065$63.436$58.00$61.261M
Oct 23, 2026$67.20$67.40$55.00$56.152.56M
Oct 22, 2026$68.02$68.85$63.50$67.14549.51K
Oct 21, 2026$69.16$71.5299$68.25$68.94832.75K
Oct 20, 2026$66.52$70.87$66.01$68.74719.51K
Oct 19, 2026$64.99$66.69$64.07$66.29505.21K
Oct 16, 2026$69.13$70.20$62.49$63.61644.55K
Oct 15, 2026$68.50$72.70$66.3495$70.22796.65K
Oct 14, 2026$64.13$69.325$63.50$68.61962.13K
Oct 13, 2026$62.70$66.41$62.01$64.96527.13K
Oct 12, 2026$67.33$67.33$63.50$63.82491.18K
Oct 9, 2026$68.45$69.73$67.22$67.33405.11K
Oct 8, 2026$67.41$67.94$64.495$67.73734.79K
Oct 7, 2026$70.31$71.43$68.39$68.53659.34K
Oct 6, 2026$76.53$79.68$70.24$71.52816.9K
Oct 5, 2026$73.35$77.20$72.04$76.27855.22K

Latest WGS news

The latest Smart Investors Daily articles mentioning WGS.

Stock researchCompany · Overview

WGS research

Overview

Company profile and research snapshot.

Company profile

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$153.75
Implied upside
—
Analysts
13
WGS recent ratings
DateFirmRatingTarget
Oct 1, 2026GuggenheimBuy—
Aug 4, 2026Canaccord GenuityBuy—
Aug 4, 2026BTIGBuy—
Jun 29, 2026GuggenheimBuy—
Jun 23, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

GAITHERSBURG, Md., October 23, 2026--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By